Receive The Newest Study Notifications

MALVERN, Pa. and SAN DIEGO, Oct. 15, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced...

Using virtual, cloud-based, interconnected computing techniques applied to 51,000 variables, researchers at Georgetown University Medical Center and colleagues reduced the time needed to assess a cancer patient's tumor profile and suitability for clinical trials from...

Catalent, a global leader in clinical supply services, today announced that Mark Woolf, its Director of Depot Networks, will present at the upcoming 6th Annual Global Clinical Supplies Group (GCSG) European Knowledge Forum, to be held at the Miragem Hotel, Cascais,...

ALLENTOWN, Pa., Oct. 14, 2019 /PRNewswire/ -- Yourway, the only truly integrated premium courier and clinical packager in the industry, announced its establishment of a new location within the European Union providing storage and distribution services, including...

First patient enrolled in registration-directed Phase 2 clinical trial of RP1 in combination with Regeneron and Sanofi’s Libtayo® in CSCC New clinical trial planned of RP1 as monotherapy in organ transplant patients with CSCC Initial clinical data with RP1 strongly...

Bottom Line: Many adult cigarette smokers start before they turn 21 and this randomized clinical trial of volunteer participants tested how effective the smoking-cessation medication varenicline was in helping adolescents and young adults to quit. The 157 volunteers...

Pfizer announced results from its Phase III clinical trial, JADE MONO-1, of abrocitinib in moderate to severe atopic dermatitis. The drug met all the co-primary and key secondary endpoints related to skin clearance and itch relief compared to placebo. Abrocitinib is...

ALLENTOWN, Pa., Oct. 14, 2019 /PRNewswire/ -- Yourway, the only truly integrated premium courier and clinical packager in the industry, announced its establishment of a new location within the European Union providing storage and distribution services, including...

MILL VALLEY, Calif. and MELBOURNE, Australia, Oct. 14, 2019 /PRNewswire/ -- Collaborative Medicinal Development, LLC) ("CMD"), a clinical stage biopharmaceutical company with a portfolio of candidates for treatment of neurological and neuropsychiatric diseases,...

Mark Terry for Biospace writes: ReveraGen BioPharma presented topline data from an 18-month treatment of Duchenne muscular dystrophy (DMD) patients with vamorolone, a first-in-class steroidal anti-inflammatory. It is being developed as an alternate to corticosteroids...

Patricia Anacio for ALS Today writes: BrainStorm Cell Therapeutics announced that the Phase 3 clinical trial of its cell therapy candidate NurOwn in 200 amyotrophic lateral sclerosis (ALS) patients is fully enrolled and treatment is underway. The randomized,...

REDWOOD CITY, Calif., Oct. 11, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc  (Nasdaq: MNLO), a late-stage biopharmaceutical company, presented results from its successful Phase 2 clinical trial of serlopitant for the treatment of pruritis in patients with psoriasis...

NEW YORK, Oct. 11, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that it has fully enrolled the 200-patient Phase 3 clinical trial evaluating...

MENLO PARK, Calif., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (GERN) today announced that the first patient has been dosed in the IMerge Phase 3 clinical trial to evaluate imetelstat, a first-in-class telomerase inhibitor, in lower risk myelodysplastic...

RALEIGH, N.C., Oct. 10, 2019 /PRNewswire/ -- Bryn Pharma, LLC ("Bryn") is a privately held pharmaceutical company dedicated to finding a better way for patients and caregivers to treat anaphylaxis. Bryn has developed an epinephrine nasal spray, a disruptive innovation...

Fulcrum Equity Partners leads investment round, along with Bee Partners and Atrium Health, to support Florence creating a new type of research network that speeds progress. ATLANTA, Oct. 10, 2019 /PRNewswire/ -- Florence, an Atlanta-based clinical trials software...

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in an exploratory Phase 2 clinical trial evaluating the ability of defibrotide to prevent neurotoxicity in patients with relapsed or refractory diffuse large B-cell...

Successful completion of Phase 2 monotherapy trial paves way for Phase 3 trials in China in early 2020 CAMBRIDGE, Mass. & ROTTERDAM, The Netherlands & SHANGHAI--(BUSINESS WIRE)--Sixth paragraph, second sentence should read: "DED is more prevalent in Asia; over...

BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced dosing of the first patient in HER2CLIMB-02, a randomized phase 3 clinical trial evaluating investigational agent tucatinib versus placebo, in combination with standard-of-care...

WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that dosing has...